Linezolid Krka

Linezolid, the active ingredient in Linezolid Krka, is an oxazolidinone presented as an oral tablet for oral use. It treats serious Gram‑positive bacterial infections, including MRSA and VRE, in adult patients.

GNH USA supplies Linezolid Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Linezolid is an antibacterial agent used for infections caused by Gram‑positive bacteria. - Complicated skin and soft tissue infections: effective against the causative Gram‑positive organisms, helping to resolve the infection. - Community‑acquired bacterial pneumonia: eradicates the responsible pathogens, improving respiratory function. - Methicillin‑resistant Staphylococcus aureus (MRSA) infections: provides a treatment option when other agents fail. - Vancomycin‑resistant Enterococcus (VRE) infections: offers activity against resistant strains. - Other serious Gram‑positive bacterial infections: broad coverage for difficult‑to‑treat pathogens.

Adverse reactions may occur with linezolid therapy and should be monitored.

Common Side Effects: - Nausea - Diarrhea - Headache - Vomiting - Metallic taste - Insomnia

Serious or Rare Side Effects: - Thrombocytopenia - Peripheral neuropathy - Serotonin syndrome - Myelosuppression - Lactic acidosis - Severe allergic reactions (e.g., anaphylaxis)

Use of linezolid requires careful clinical assessment and monitoring. - Renal impairment: dose adjustment may be needed in severe renal dysfunction. - Hepatic impairment: monitor liver function tests during therapy. - Concomitant serotonergic drugs: avoid due to risk of serotonin syndrome. - Hematologic monitoring: regular blood counts are recommended. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Linezolid can interact with several drug classes, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): potential serotonin syndrome. - Rifampin: may significantly lower linezolid plasma concentrations.

Moderate Interactions (Monitor Closely): - Warfarin: may increase INR, requiring closer coagulation monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened bleeding risk. - Antacids containing magnesium or aluminum: may affect absorption, consider timing adjustments.